A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.

Cell Rep Med · 2023 · PMC10040383 · PMID 36868236

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although there was a trend between tumor CD1d expression and type 1 NKT and Vγ9Vδ2-T cell-mediated lysis, this did not reach statistical significance ( Figures S4 E–S4G).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.